Our solutions for advanced therapies
When gene expression shapes the safety, efficacy or durability of a cell or gene therapy, standard viral promoters rarely give you the control you need: the right cell type, level and conditions, within the limits of your vector. Annogen designs, selects and validates expression systems by large-scale measurement in the cells that matter, not by computational prediction alone, and the elements we deliver are yours to own.
Gene expression systems tailored for your therapy.
Typical solutions for advanced therapies
Saturation mutagenesis & base-editing maps
Exhaustively validate the functional impact of each sequence variant in a promoter or enhancer to improve their function and provide therapeutic base editing roadmaps.
Other expression engineering solutions
Empirically screening for the most optimal non-coding elements including 3’UTRs, insulators, silencers and capsids.
Integration site analysis
Exhaustively screen genome-wide expression loci to identify the strongest, most stable for your therapeutic transgene.
Manufacturing cell lines
Improve titers and expression stability in manufacturing cell lines for recombinant proteins and viral vectors through dedicated screens.
Lab-in-a-loop training data
Generate bespoke, highly sensitive data sets to train and improve your ML/AI models.
Clinical results we are proud of
We combine high-throughput experimental screening with AI-based optimizations to identify what performs, not just what looks promising in a model.
With more than a decade of promoter development experience, we can assess feasibility early, guide realistic timelines, and tell you when expectations need adjusting.
When existing data does not cover your needs, we generate the dataset your promoter design needs in the most appropriate cell type and model system.
Why choose Annogen?
What sets our approach apart when you seek the best expression control for your therapy.
Measured, not predicted
We identify regulatory elements by iterative, large-scale experimental screening in the relevant cells, then apply AI on top of that measured data. You get patentable elements that perform in practice, not candidates that only looked promising in a model.
Experience improves outcomes
With more than a decade of promoter development experience, with promoters currently used in the clinic, we can assess feasibility early, guide realistic timelines and tell you when expectations need adjusting.
Where models cannot go
Because we measure rather than predict, we can develop promoters for targets with no prior data, including novel small-molecule-inducible systems, and screen them at scale directly in vivo, in the model that reflects your therapy.
Our platforms
Design gene expression around two critical choices: the regulatory sequence that controls your gene, and the genomic location where it performs.
AIM™
Find the genomic locations where your transgene performs reliably.
AIM™ maps integration sites at scale while in parallel measuring expression for each site. This reveals where expression is stable, controlled, and best suited to your system.
SuRE™
Find the regulatory sequences that give your gene the right expression behavior.
SuRE™ screens promoters, enhancers and regulatory variants at scale to identify what delivers the right strength, specificity and control.
Together, let’s shape what comes next.
Exhaustive screening and design of bespoke promoters and expression loci for any tissue, any organism. We believe control of gene expression is the foundation of the next generation of therapeutics and crops.
Trusted by
